Table 2 Summary of linear regression analyses with MoCA score as the outcome
From: Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study
Independent variable | Simple Linear Regression | Multiple Linear Regression | ||
|---|---|---|---|---|
β Coefficient (95% CI) | P value | β Coefficient (95% CI) | Adjusted P value | |
Age (per 10-year increase) | −1.13 (− 1.42, − 0.84) | <.001* | − 0.58 (− 1.00, − 0.17) | .006* |
Sex | ||||
 Male | 0.00 (reference) | – | 0.00 (reference) | – |
 Female | 0.52 (−0.01, 1.04) | .053 | 0.74 (0.03, 1.45) | .041* |
Education | ||||
  ≤ 12 years | 0.00 (reference) | – | 0.00 (reference) | – |
  > 12 years | 1.46 (0.97, 1.95) | <.001* | 0.51 (−0.18, 1.20) | .149 |
Disease duration | 0.01 (−0.01, 0.03) | .496 | 0.03 (−0.01, 0.06) | .119 |
Disease severity | ||||
 Remission (DAS28 ≤ 2.6) | 0.00 (reference) | – | 0.00 (reference) | – |
 Low (2.61 < DAS28 ≤ 3.2) | −0.33 (−1.27, 0.62) | .497 | 0.60 (− 0.48, 1.68) | .275 |
 Moderate (3.21 < DAS28 ≤ 5.1) | −0.95 (− 1.72, − 0.18) | .016* | − 1.10 (− 1.90, − 0.30) | .008* |
 High (DAS28 > 5.1) | −1.33 (− 2.34, − 0.33) | .009* | −1.41 (− 2.45, − 0.36) | .008* |
RF | ||||
 Negative | 0.00 (reference) | – | 0.00 (reference) | – |
 Positive | −0.68 (−1.28, − 0.09) | .025* | −0.68 (− 1.61, 0.25) | .150 |
Anti-CCP | ||||
 Negative | 0.00 (reference) | – | 0.00 (reference) | – |
 Positive | −0.36 (− 0.94, 0.22) | .225 | − 0.76 (− 1.66, 0.14) | .097 |
RA Medication | ||||
 csDMARD + TNFi | 0.00 (reference) | – | 0.00 (reference) | – |
 csDMARD only | 0.41 (−0.19, 1.02) | .183 | 0.25 (−0.68, 1.17) | .601 |
 TNFi only | 0.55 (− 0.31, 1.41) | .208 | 0.72 (−0.91, 2.34) | .387 |
Taking prednisolone | ||||
 No | 0.00 (reference) | – | 0.00 (reference) | – |
 Yes | −0.14 (−1.14, 0.87) | .788 | 0.86 (−0.70, 2.42) | .277 |
Taking NSAID | ||||
 No | 0.00 (reference) | – | 0.00 (reference) | – |
 Yes | − 0.15 (− 0.86, 0.56) | .679 | 0.97 (− 0.01, 1.95) | .053 |